Skip to content
synovial sarcoma foundation
  • About
    • Mission
    • Initiatives
    • Affiliations
    • Leadership
    • Board of Directors
    • Medical Advisory Board
    • Careers
  • Resources
    • Synovial Sarcoma FAQ
    • Treatments
    • Clinical Trials & Therapies
    • Synovial Sarcoma Patient Survey
    • Synovial Sarcoma Tumor Board
    • Patient Stories
    • Patient Resources
    • Eddie’s Story
    • Video Resources
    • SSF Ambassador Program
  • Research Programs
    • Clinical Research
    • Tumor Glow
    • Synovial Sarcoma Registry
  • Latest News
Donate

Send us a note

Please fill out the form below and we will gladly respond as soon as possible.



    Tumor Board, Research

    Tumor Board Continues to Grow with New Members to Advance Breakthrough Treatments for Synovial Sarcoma Patients

    July 22, 2025 joshs Comments Off on Tumor Board Continues to Grow with New Members to Advance Breakthrough Treatments for Synovial Sarcoma Patients
    A modern, multi-story medical research center is illuminated at dusk, with large glass windows and well-lit interiors. The building is labeled “Houston Methodist Research Institute.” City lights are visible in the background.

    The National Synovial Sarcoma Tumor Board, a dedicated multidisciplinary team committed to improving outcomes for individuals affected by synovial sarcoma, is pleased to announce the ongoing expansion of its membership. This growth reflects our steadfast dedication to fostering innovative treatment strategies and providing personalized care for more patients nationwide.

    We are proud to share that the Tumor Board now includes 42 participating institutions, strengthening our collective expertise and reach. Recent additions include Duke Health in North Carolina, Johns Hopkins University in Maryland, and the University of Minnesota/Masonic Cancer Center in Minnesota. These new members, along with our existing institutions, greatly enhance our ability to develop and implement cutting-edge, individualized treatment plans.

    “Our goal is to push the boundaries of current treatment approaches and offer hope to patients facing this challenging diagnosis,” said Nathan Imperiale, Chairman of the Synovial Sarcoma Foundation. “The new medical professionals bring valuable insights and experience, which will help us refine our strategies and reach more patients who can benefit from innovative therapies.”

    The Tumor Board’s continued growth underscores the foundation’s commitment to leading advancements in synovial sarcoma treatment and ensuring that every patient receives expert, tailored care. If your doctor or care team is not currently participating, please share this information with them! The Synovial Sarcoma Tumor Board offers an incredible opportunity for medical professionals to collaborate with leading experts and provide the best possible care for their patients.

    The current list of participating institutions includes:

    • Atrium Health
    • Augusta Oncology
    • Barnes-Jewish Hospital
    • CancerCare Manitoba
    • Cedars-Sinai
    • Children’s Hospital Colorado
    • Children’s Hospital Los Angeles
    • Children’s Hospital Medical Center of Akron
    • Children’s Hospital of Orange County
    • Children’s Hospital of Philadelphia
    • Cincinnati Children’s Hospital
    • City of Hope
    • Cleveland Clinic
    • Columbia
    • Dana-Farber/Harvard Cancer Center
    • Dell Children’s Medical Center of Central Texas
    • John Hopkins
    • Kaiser Permanente Northern California
    • Lucile Packard Children’s Hospital
    • Maine Health
    • Mayo AZ
    • Mayo Clinic
    • MD Anderson Cancer Center
    • MD Anderson in Phoenix
    • Memorial Sloan Kettering Cancer Center
    • Nationwide Children’s Hospital
    • Northwestern Medicine
    • NYU Langhorne
    • Penn Medicine
    • Roswell Park Comprehensive Cancer Center
    • Seattle Children’s Hospital
    • St Jude Children’s Research Hospital
    • Stanford
    • UC Davis
    • UC San Diego
    • UC Santa Cruz
    • UCLA Health
    • UCSF Benioff Children’s Hospital
    • University of Rochester
    • University of Alabama at Birmingham
    • University of Arkansas for Medical Sciences
    • University of Colorado
    • University of Miami
    • University of Utah Health / Primary Children’s Hospital
    • University of Washington
    • UT Southwestern / Simmons Cancer Center-Dallas
    • Valley Children’s Hospital
    • Vanderbilt

    For more information about the Tumor Board and how it is working to transform synovial sarcoma treatment, please visit our website.

    • innovate treaments
    • Nathan Imperiale
    • National Tumor Board
    • patient advocates
    • Synovial Sarcoma Foundation
    joshs

    Post navigation

    Previous
    Next

    Search

    Categories

    • Black Flag Racing (2)
    • Case Study (5)
    • Children (1)
    • CHOP (3)
    • Clinical Trial (4)
    • Development (12)
    • Dr. Theodore Laetsch (3)
    • Education (27)
    • Europe Expansion (1)
    • Healthcare (13)
    • Latest News (22)
    • Patient Story (1)
    • Programs (1)
    • Rare Cancer (7)
    • Rare Cancer Funding (2)
    • Research (21)
    • SSF Ambassador Program (1)
    • Synovial Sarcoma Conference (2)
    • Synovial Sarcoma Registry (7)
    • Teresa Belluco (1)
    • Tumor Board (2)

    Recent posts

    • A doctor in a white coat with a stethoscope around their neck holds a tablet device, standing in a medical setting with a patient lying on a bed in the background.
      Synovial Sarcoma of the Tibial Nerve: A Case of Diagnostic Ambiguity and Limb Salvage
    • A scientist wearing blue gloves adjusts a microscope slide.
      Can We Reactivate T Cells After TCR-T Therapy Stops Working?
    • Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
      Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    Tags

    #AYACancer #CancerResearch #CaseReport #CellTherapy #ClinicalTrials #Immunotherapy #KnowYourOptions #MAGEA4 #MolecularDiagnostics #NYESO1 #PatientAdvocacy #RareCancer #RareDisease #Sarcoma #SarcomaAwareness #SoftTissueSarcoma #SS18SSX #SynovialSarcoma #SynovialSarcomaFoundation #TumorBoard Afami-cel Afamitresgene autoleucel Cancer Research CHOP immunotherapy MAGE-A4 synovial sarcoma NY-ESO-1 synovial sarcoma precision medicine Rare Cancer rare cancer research rare soft tissue sarcoma research sarcoma research sarcoma treatment soft tissue sarcoma Synovial Sarcoma synovial sarcoma biomarker testing synovial sarcoma diagnosis Synovial Sarcoma Foundation synovial sarcoma immunotherapy synovial sarcoma treatment T-Cell Therapy targeted therapy TCR Therapy TECELRA

    Related posts

    A scientist wearing blue gloves adjusts a microscope slide.
    Clinical Trial, Development

    Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    November 3, 2026 ayushis Comments Off on Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    A new pilot trial at Northwestern University is asking one of the most important questions in synovial sarcoma treatment: when TCR-T therapy stops working, are the T cells truly gone, or can they be brought back to life? Background: The Promise and the Limit of TCR-T Therapy TCR-T cell therapy represents a major advance for […]

    Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
    Latest News, Synovial Sarcoma Registry

    Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    October 28, 2026 ayushis Comments Off on Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    A new study in Advanced Science (October 12, 2026) shows what becomes possible when patients donate tumor tissue and researchers pair it with detailed clinical and genetic data. The same idea drives the Synovial Sarcoma Registry and Biorepository, and every patient who joins makes the next study possible. What the study found Over ten years, […]

    Close-up of blue gloved hands adjusting a microscope with two visible objective lenses, focusing on a glass slide in a laboratory setting.
    Education, Research

    The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    September 14, 2026 ayushis Comments Off on The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    A new study published in PLOS One by Ji-Yong Sung, Jin-Hong Kim, and Yi-Jun Kim from Seoul National University and Ewha Womans University, South Korea, examines a type of cell found in the tissue surrounding tumors, called cancer-associated fibroblasts (CAFs), and asks whether they can predict how a sarcoma patient will respond to immunotherapy. What […]

    The Synovial Sarcoma Foundation is a registered 501(c)(3) nonprofit organization. Tax ID number is 33-4027591. Contributions to the Synovial Sarcoma Foundation are tax-deductible to the extent permitted by law.

    • Terms & conditions
    • Privacy policy
    synovial sarcoma foundation
    • community@synovialsarcoma.org
    1025 Thomas Jefferson St. NW, Suite W-3200, Washington DC 20007
    Facebook-f X-twitter Linkedin

    Navigation

    • About
    • Research Programs
    • Patient Stories
    • Resources

    Stay in touch